Country/Region: South Korea
PE Guidelines

Pharmaceutical Economic Evaluation Guidelines (January 2006)
PDF in Korean

PE Guidelines Source:

Health Insurance Review & Assessment Service
http://www.hira.or.kr/

Additional Information:

PE Guideline Key Features – in Progress

Last Webpage Update: Tuesday, May 17, 2011

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Pharmaceutical Economic Evaluation Guidelines (January 2006) 
Affiliation of authors
 
Purpose of the document
 
Standard reporting format included
 
Disclosure
 
Target audience of funding/ author's interests
 
Perspective
 
Indication
 
Target population
 
Subgroup analysis
 
Choice of comparator
 
Time horizon
 
Assumptions required
 
Preferred analytical technique
 
Costs to be included
 
Source of costs
 
Modeling
 
Systematic review of evidences
 
Preference for effectiveness over efficacy
 
Preferred outcome measure
 
Preferred method to derive utility
 
Equity issues stated
 
Discounting costs
 
Discounting outcomes
 
Sensitivity analysis-parameters and range
 
Sensitivity analysis-methods
 
Presenting results
 
Incremental analysis
 
Total costs vs effectiveness (cost/effectiveness ratio)
 
Portability of results (Generalizability)
 
Financial impact analysis
 
Mandatory or recommended or voluntary
 

Country Selection Page | PE Guidelines Index Page